Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 23.5% in February

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 1,300 shares, a drop of 23.5% from the February 13th total of 1,700 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 19,600 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Addex Therapeutics

A hedge fund recently bought a new stake in Addex Therapeutics stock. Citadel Advisors LLC acquired a new stake in Addex Therapeutics Ltd (NASDAQ:ADXN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 1.14% of Addex Therapeutics as of its most recent SEC filing. Institutional investors own 16.14% of the company’s stock.

Addex Therapeutics Stock Performance

Shares of ADXN stock opened at $7.46 on Tuesday. Addex Therapeutics has a 1 year low of $6.67 and a 1 year high of $27.90. The stock has a fifty day moving average of $7.74 and a two-hundred day moving average of $8.77. The firm has a market capitalization of $7.91 million, a PE ratio of -21.94 and a beta of 1.76.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.